retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Reta GLP-3R (Retatrutide) 10mg |

I see patients who are really sick autoimmune conditions, toxic overload, chronic inflammation, neurological issues

Oxidative stress and alterations in the GSH metabolism of the brain have been connected with many neurological and neurodegenerative diseases as recently summarized (Asanuma and Miyazaki 2021

IGF-1 is vital for new muscle fiber formation, robust collagen production, and the accelerated healing of connective tissuesmaking it a key focus for injury recovery and physical rehabilitation studies

In high doses, it can cause abdominal pain, nausea, diarrhea, and dizziness

To clarify the upstream regulatory mechanism of miR-29b-3p under Gln deprivation conditions, we focused on c-Myc as a key candidate transcription factor

Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S